clinical trial · NCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Biopharma SRL·phase3·not yet recruiting·n = 120
Ocular Myasthenia GravisRozanolixizumabPlacebo
brief summary
The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
started
May 29, 2026
primary completion
Dec 1, 2028
completion
Jan 22, 2029
last updated
Mar 17, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol